171 related articles for article (PubMed ID: 33964840)
1. ANTIHYPERTENSIVE AND CARDIOPROTECTIVE EFFECTS OF EPOXYEICOSATRIENOIC ACID ANALOGS AND SOLUBLE EPOXIDE HYDROLASE INHIBITORS (REVIEW).
Papiashvili N; Gongadze N; Bakuridze A; Bakuridze K
Georgian Med News; 2021 Mar; (312):125-132. PubMed ID: 33964840
[TBL] [Abstract][Full Text] [Related]
2. Soluble epoxide hydrolase inhibitors and heart failure.
Qiu H; Li N; Liu JY; Harris TR; Hammock BD; Chiamvimonvat N
Cardiovasc Ther; 2011 Apr; 29(2):99-111. PubMed ID: 20433684
[TBL] [Abstract][Full Text] [Related]
3. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
[TBL] [Abstract][Full Text] [Related]
4. The soluble epoxide hydrolase as a pharmaceutical target for hypertension.
Chiamvimonvat N; Ho CM; Tsai HJ; Hammock BD
J Cardiovasc Pharmacol; 2007 Sep; 50(3):225-37. PubMed ID: 17878749
[TBL] [Abstract][Full Text] [Related]
5. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo.
Ai D; Fu Y; Guo D; Tanaka H; Wang N; Tang C; Hammock BD; Shyy JY; Zhu Y
Proc Natl Acad Sci U S A; 2007 May; 104(21):9018-23. PubMed ID: 17495027
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.
Neckář J; Kopkan L; Husková Z; Kolář F; Papoušek F; Kramer HJ; Hwang SH; Hammock BD; Imig JD; Malý J; Netuka I; Ošťádal B; Červenka L
Clin Sci (Lond); 2012 Jun; 122(11):513-25. PubMed ID: 22324471
[TBL] [Abstract][Full Text] [Related]
8. Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics: 2019 Lewis K. Dahl Memorial Lecture.
Imig JD; Jankiewicz WK; Khan AH
Hypertension; 2020 Jul; 76(1):3-15. PubMed ID: 32475311
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.
Kim J; Yoon SP; Toews ML; Imig JD; Hwang SH; Hammock BD; Padanilam BJ
Am J Physiol Renal Physiol; 2015 Jan; 308(2):F131-9. PubMed ID: 25377915
[TBL] [Abstract][Full Text] [Related]
10. Soluble epoxide hydrolase in atherosclerosis.
Wang YX; Ulu A; Zhang LN; Hammock B
Curr Atheroscler Rep; 2010 May; 12(3):174-83. PubMed ID: 20425256
[TBL] [Abstract][Full Text] [Related]
11. Soluble epoxide hydrolase: gene structure, expression and deletion.
Harris TR; Hammock BD
Gene; 2013 Sep; 526(2):61-74. PubMed ID: 23701967
[TBL] [Abstract][Full Text] [Related]
12. CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators.
Shi Z; He Z; Wang DW
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744996
[TBL] [Abstract][Full Text] [Related]
13. Inside epoxyeicosatrienoic acids and cardiovascular disease.
Tacconelli S; Patrignani P
Front Pharmacol; 2014; 5():239. PubMed ID: 25426071
[TBL] [Abstract][Full Text] [Related]
14. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
15. Epoxyeicosanoids in hypertension.
Imig JD
Physiol Res; 2019 Oct; 68(5):695-704. PubMed ID: 31475560
[TBL] [Abstract][Full Text] [Related]
16. Vascular Endothelial Over-Expression of Human Soluble Epoxide Hydrolase (Tie2-sEH Tr) Attenuates Coronary Reactive Hyperemia in Mice: Role of Oxylipins and ω-Hydroxylases.
Hanif A; Edin ML; Zeldin DC; Morisseau C; Falck JR; Nayeem MA
PLoS One; 2017; 12(1):e0169584. PubMed ID: 28056085
[TBL] [Abstract][Full Text] [Related]
17. A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction.
Xu DY; Davis BB; Wang ZH; Zhao SP; Wasti B; Liu ZL; Li N; Morisseau C; Chiamvimonvat N; Hammock BD
Int J Cardiol; 2013 Aug; 167(4):1298-304. PubMed ID: 22525341
[TBL] [Abstract][Full Text] [Related]
18. The involvement of soluble epoxide hydrolase in the development of cardiovascular diseases through epoxyeicosatrienoic acids.
Jiang S; Han S; Wang DW
Front Pharmacol; 2024; 15():1358256. PubMed ID: 38628644
[TBL] [Abstract][Full Text] [Related]
19. Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor.
Sanders WG; Morisseau C; Hammock BD; Cheung AK; Terry CM
Am J Physiol Cell Physiol; 2012 Aug; 303(3):C278-90. PubMed ID: 22621785
[TBL] [Abstract][Full Text] [Related]
20. Novel soluble epoxide hydrolase inhibitor protects mitochondrial function following stress.
Batchu SN; Lee SB; Samokhvalov V; Chaudhary KR; El-Sikhry H; Weldon SM; Seubert JM
Can J Physiol Pharmacol; 2012 Jun; 90(6):811-23. PubMed ID: 22624559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
